Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

NCT07157306 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Gecacitinib Combined With Donafenib and PD-1 Inhibitor

Sponsor

Tianjin Medical University Cancer Institute and Hospital